Epirubicin

🧮 Dose calculator

Breast cancer (hormonal therapy) · Regimen source: FDA Ellence · 2.2

• • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Ellence · 2.2
• • Calculator gives the lower bound. CEF-120: 60 mg/m² days 1 and 8; FEC-100: 100 mg/m² day 1. FDA Ellence · 2.2

Enter age and weight.

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Ellence · 8.1

  “Risk Summary Based on findings from animal studies and its mechanism of action, ELLENCE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] ; avoid the use of ELLENCE during the 1 st trimester.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Ellence · 8.2

  “Because of the potential for serious adverse reactions in the breastfed child, advise lactating women not to breastfeed during treatment with ELLENCE and for at least 7 days after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ellence · 8.4

  “Safety and effectiveness of ELLENCE have not been established in pediatric patients.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ellence · 8.5

  “In elderly female patients, closely monitor for increased toxicity due to the risk of decreased clearance of epirubicin [see Clinical Pharmacology (12.3) ].”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Ellence · 8.3

  “Contraception Females ELLENCE can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”